Canadian Cancer Trials Group Bulletins


Recent Publication

The primary publication for IND.160 -- A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours -- was recently published in the Journal of Clinical Oncology.

The authors concluded that mTOR inhibition with temsirolimus has encouraging single-agent activity in endometrial cancer which is higher in chemotherapy-naive patients than in chemotherapy-treated patients and is independent of PTEN status. The difference in activity according to prior therapy should be factored into future clinical trial designs.

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the Canadian Cancer Trials Group (ONLINE). J Clin Oncol 2011.